Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock Holdings Boosted by Barclays PLC

Barclays PLC lifted its position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 281.8% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 38,218 shares of the company’s stock after buying an additional 28,208 shares during the period. Barclays PLC owned approximately 0.08% of Mineralys Therapeutics worth $463,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. SG Americas Securities LLC acquired a new position in Mineralys Therapeutics during the third quarter worth about $110,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Mineralys Therapeutics by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,564 shares of the company’s stock worth $116,000 after purchasing an additional 3,732 shares during the last quarter. Federated Hermes Inc. grew its stake in shares of Mineralys Therapeutics by 100.0% in the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock worth $140,000 after purchasing an additional 6,000 shares during the last quarter. The Manufacturers Life Insurance Company bought a new stake in shares of Mineralys Therapeutics in the 2nd quarter worth approximately $145,000. Finally, PDT Partners LLC acquired a new stake in Mineralys Therapeutics during the third quarter valued at approximately $148,000. Institutional investors and hedge funds own 84.46% of the company’s stock.

Insider Buying and Selling

In other news, insider David Malcom Rodman sold 25,482 shares of the company’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $15.03, for a total value of $382,994.46. Following the transaction, the insider now directly owns 135,974 shares of the company’s stock, valued at approximately $2,043,689.22. This represents a 15.78 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Adam Scott Levy sold 10,757 shares of Mineralys Therapeutics stock in a transaction on Monday, January 13th. The shares were sold at an average price of $9.10, for a total value of $97,888.70. Following the sale, the chief financial officer now directly owns 226,097 shares of the company’s stock, valued at approximately $2,057,482.70. The trade was a 4.54 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 54,572 shares of company stock valued at $646,980. Corporate insiders own 33.24% of the company’s stock.

Mineralys Therapeutics Trading Down 2.7 %

Shares of MLYS opened at $9.24 on Friday. The business’s 50-day moving average price is $12.18 and its 200 day moving average price is $12.45. The stock has a market capitalization of $459.87 million, a P/E ratio of -2.83 and a beta of 1.49. Mineralys Therapeutics, Inc. has a 1-year low of $7.95 and a 1-year high of $16.91.

Mineralys Therapeutics (NASDAQ:MLYS) last released its earnings results on Monday, November 11th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.30). During the same quarter in the prior year, the firm posted ($0.57) earnings per share. On average, research analysts predict that Mineralys Therapeutics, Inc. will post -3.63 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Mineralys Therapeutics in a research report on Tuesday, November 12th.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.